Translocations involving the anaplastic lymphoma kinase (ALK) represent common oncogenic events in 4%-5% of patients with non–small cell lung cancer (NSCLC).1 Echinoderm microtubule-associated protein-like 4 (EML4) acts as a translocation partner and is involved most frequently in ALK translocations leading to increased activity of the ALK tyrosine kinase.2 Activating ALK translocations promote proliferation and tumor growth. Here, ALK is linked to neoplasm.